Compare IPSC & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPSC | BCIC |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 162.3M |
| IPO Year | 2021 | N/A |
| Metric | IPSC | BCIC |
|---|---|---|
| Price | $2.33 | $11.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 976.3K | 54.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 16.39% |
| EPS Growth | ★ 29.07 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $6,589,000.00 | N/A |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | $14.87 |
| P/E Ratio | $20.64 | ★ $7.27 |
| Revenue Growth | ★ 194.81 | N/A |
| 52 Week Low | $0.34 | $11.13 |
| 52 Week High | $2.71 | $13.50 |
| Indicator | IPSC | BCIC |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 35.58 |
| Support Level | $0.49 | $11.13 |
| Resistance Level | $2.71 | $12.43 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 79.33 | 14.41 |
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.